You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

4 Results
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Updated
Feb 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Updated
Feb 2026
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Updated
Feb 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Rectal
Intent: Neoadjuvant
Jan 2026